Sandra Horning, MD
The FDA has accepted a supplemental biologics license application (sBLA) for bevacizumab (Avastin) for the first-line treatment of advanced ovarian cancer, according to Genentech, the manufacturer of the angiogenesis inhibitor.
In both trials, the bevacizumab-containing regimens resulted in superior objective response. The ORR with bevacizumab was 78% in both studies compared with 56% in GOG-0213 and 57% in OCEANS for the chemotherapy arms.
- FDA Accepts Genentech’s Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women with Advanced Ovarian Cancer. Genentech. http://bit.ly/2i548hf. Accessed October 26, 2017.
- FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy to Treat Women with Platinum-Resistant Recurrent Ovarian Cancer. Genentech. http://bit.ly/2z9buev. Accessed October 26, 2017.
- FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer. Genentech. http://bit.ly/2h2DQeB. Accessed October 26, 2017.
... to read the full story